Volume 5 Issue 2
Dec.  2021
Turn off MathJax
Article Contents
Article Navigation >  Blood&Genomics  > 2021  >  5(2): 121-127
Jingya Zhao, Zhixin Liu, Dandan Yin, Shijie Mu. TCEP-HCl can resolve the daratumumab interference[J]. Blood&Genomics, 2021, 5(2): 121-127. doi: 10.46701/BG.2021022021124
Citation: Jingya Zhao, Zhixin Liu, Dandan Yin, Shijie Mu. TCEP-HCl can resolve the daratumumab interference[J]. Blood&Genomics, 2021, 5(2): 121-127. doi: 10.46701/BG.2021022021124
shu

TCEP-HCl can resolve the daratumumab interference

doi: 10.46701/BG.2021022021124
  • 1.

    Department of Transfusion Medicine, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi 710038, China

  • 2.

    Department of Transfusion Medicine, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China

  • 3.

    Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi 710038, China

More Information
  • Corresponding author: Dandan Yin, Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi 710038, China. E-mail: ydandan@fmmu.edu.cn; Shijie Mu, Department of Transfusion Medicine, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi 710038, China. E-mail: musj1963@fmmu.edu.cn
  • Received Date: 2021-08-02
  • Accepted Date: 2021-12-01
  • Rev Recd Date: 2021-11-30
    • Available Online: 2022-01-06
  • Publish Date: 2021-12-31
    Abstract
  • Daratumumab (DARA) is a human CD38 IgG1 monoclonal antibody that has significant therapeutic effects on multiple myeloma (MM). However, DARA may interfere with the indirect antiglobulin test (IAT) used to test for MM. At present, there are defects in the popular strategies for IAT anti-human globulin reactions caused by anti-CD38 monoclonal antibody drugs. Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) is a new and effective solution to eliminate DARA's interference with the IAT. To verify its effect, the following experiments were done. After TCEP-HCl was administered to red blood cells (RBCs), the expression level of CD38 antigen on RBCs was determined by flow cytometry. Serological experiments were performed to verify the effects of TCEP-HCl on different blood groups of RBCs. The results showed that DARA could cause false-positive reaction in IAT, and the CD38 antigen on the membranes of RBCs decreased after TCEP-HCl treatment. Serological results showed that TCEP-HCl did not damage other blood group antigens on RBCs, except for Kell antigens. Indirect antiglobulin tests appeared normal after treatment with the TCEP-HCl reagent. The conclusion is that TCEP-HCl can resolve daratumumab interference in the IAT.

     

    • △These authors contributed equally to this work.
    FullText(HTML)
  • loading
    • References(22)
  • [1]
    Van De Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future[J]. Blood, 2018, 131(1): 13−29. doi: 10.1182/blood-2017-06-740944
    [2]
    Plesner T, Arkenau HT, Gimsing P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma[J]. Blood, 2016, 128(14): 1821−1828. doi: 10.1182/blood-2016-07-726729
    [3]
    Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study[J]. Lancet, 2020, 396(10245): 186−197. doi: 10.1016/S0140-6736(20)30734-0
    [4]
    Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma[J]. N Engl J Med, 2016, 375(8): 754−766. doi: 10.1056/NEJMoa1606038
    [5]
    Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma[J]. Front Immunol, 2018, 9: 1228. doi: 10.3389/fimmu.2018.01228
    [6]
    Murphy MF, Dumont LJ, Greinacher A, et al. Interference of new drugs with compatibility testing for blood transfusion[J]. N Engl J Med, 2016, 375(3): 295−296. doi: 10.1056/NEJMc1515969
    [7]
    Deneys V, Thiry C, Frelik A, et al. Daratumumab: therapeutic asset, biological trap![J]. Transfus Clin Biol, 2018, 25(1): 2−7. doi: 10.1016/j.tracli.2017.12.001
    [8]
    Petrucci M T, Vozella F. The Anti-CD38 antibody therapy in multiple myeloma[J]. Cells, 2019, 8(12): 1629. doi: 10.3390/cells8121629
    [9]
    Oostendorp M, Van Bueren JJL, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy[J]. Transfusion, 2015, 55(6 Pt 2): 1555−1562. doi: 10.1111/trf.13150
    [10]
    De Vooght KM, Oostendorp M, Van Solinge WW. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing[J]. Curr Opin Hematol, 2016, 23(6): 557−562. doi: 10.1097/MOH.0000000000000276
    [11]
    Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing[J]. Transfusion, 2016, 56(12): 2964−2972. doi: 10.1111/trf.13789
    [12]
    Dizon MF. The challenges of daratumumab in transfusion medicine[J]. Lab Med, 2017, 48(1): 6−9. doi: 10.1093/labmed/lmw055
    [13]
    Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing[J]. Transfusion, 2015, 55(6): 1545−1554. doi: 10.1111/trf.13069
    [14]
    Ziza KNC, Paiva TA, Mota SR, et al. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing[J]. Transfusion, 2019, 59(5): 1827−1835. doi: 10.1111/trf.15202
    [15]
    Quach H, Benson S, Haysom H, et al. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma[J]. Intern Med J, 2018, 48(2): 210−220. doi: 10.1111/imj.13707
    [16]
    Hosokawa M, Kashiwagi H, Nakayama K, et al. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)[J]. Transfusion, 2018, 58(12): 3003−3013. doi: 10.1111/trf.14900
    [17]
    Fung MK, Grossman BJ, Hillyer CD, et al. Technical manual[M]. 18th ed. Bethesda: American Association of Blood Banks, 2014.
    [18]
    Liu Z, Zeng R, Chen Q, et al. Genotyping for Kidd, Kell, Duffy, Scianna, and RHCE blood group antigens polymorphisms in Jiangsu Chinese Han[J]. Chin Med J (Engl), 2012, 125(6): 1076–1081.
    [19]
    Yeh TJ, Yeh CJ, Liu YC, et al. Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma[J]. Transfusion, 2019, 59(8): 2751−2752. doi: 10.1111/trf.15341
    [20]
    Zhou Y, Chen L, Jiang T, et al. 2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests[J]. Hematology, 2021, 26(1): 365−370. doi: 10.1080/16078454.2021.1918916
    [21]
    Branch DR. Immunotherapy: the good, the bad, the ugly, and the really ugly[J]. Transfusion, 2019, 59(2): 437−440. doi: 10.1111/trf.15142
    [22]
    Velliquette RW, Aeschlimann J, Kirkegaard J, et al. Monoclonal anti-CD47 interference in red cell and platelet testing[J]. Transfusion, 2019, 59(2): 730−737. doi: 10.1111/trf.15033
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (32) PDF downloads(3) Cited by()
    Proportional views
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-3

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return